DPN

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

Retrieved on: 
목요일, 4월 18, 2024
Health, FDA, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, VRTX, Pain, Pregabalin, Safety, NDA, Food, New Drug Application, DPN, Sciatica, Fast track (FDA), Week, Patient, Medicine, Neuropathic pain, LSR, Vertex, Vertex Pharmaceuticals, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades.
  • Following the positive Phase 3 results in acute pain announced in January 2024, the Food and Drug Administration (FDA) has granted a rolling New Drug Application (NDA) submission for suzetrigine in moderate-to-severe acute pain.
  • Suzetrigine was previously granted FDA Fast Track and Breakthrough Therapy designations in moderate-to-severe acute pain.
  • The company intends to advance its next generation NaV1.8 pain signal inhibitor VX-993 oral formulation into Phase 2 acute pain and peripheral neuropathic pain studies later this year.

EQS-News: Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions

Retrieved on: 
수요일, 4월 10, 2024
Trigeminal neuralgia, Knee, Growth, Rheumatoid arthritis, Neuropathic pain, Pain, GRM, DPN, ESG, Patient, Prednisolone, Research, Sustainalytics, Breakthrough, Glucocorticoid, Quality of life, PSNP, Research and development, Investment, Diabetic neuropathy, NOP, Kyowa Kirin, Osteoarthritis, RTX, Food, FDA, Corporation, Pharmaceutical industry

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.

Key Points: 
  • In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.
  • Grünenthal owns 51 percent of the new enterprise Grünenthal Meds and intends to acquire the remaining share in 2026.
  • Aachen, Germany, 25 March 2024 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.
  • The 2023 results were driven by strong business performance in the United States, Latin America and Europe.

NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

Retrieved on: 
목요일, 3월 14, 2024
Diagnosis, Hayashi, DPN, Diabetes, Patient, Dunker, Polyneuropathy, EKG

WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN).

Key Points: 
  • WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN).
  • The reference standard for DPN was a gold standard nerve conduction study.
  • DPNCheck combined with CVR-R had high diagnostic performance with an area under the receiver operating curve of 0.88.
  • The authors concluded "The use of DPNCheck and electrocardiogram would make the diagnosis of DPN simple, ubiquitous, and with high reproducibility and reliability."

Cloud Peritus Launches MedTech360°: Streamlining CRM Implementation in the MedTech Industry

Retrieved on: 
화요일, 4월 2, 2024
Cloud, CRM, DPN, Health, Salesforce, SAN, SVP, Patient, Marketing, Distributor, Salesforce Marketing Cloud, HCP, Medtech, Online shopping

SAN FRANCISCO, April 2, 2024 /PRNewswire/ -- In an industry as complex and dynamic as MedTech, finding solutions that simplify and accelerate CRM implementation processes is crucial.

Key Points: 
  • SAN FRANCISCO, April 2, 2024 /PRNewswire/ -- In an industry as complex and dynamic as MedTech, finding solutions that simplify and accelerate CRM implementation processes is crucial.
  • This solution is tailored to enhance the efficiency and effectiveness of CRM systems for MedTech companies.
  • MedTech360° is more than just an accelerator; it's a comprehensive strategy designed to streamline the often convoluted path to CRM optimization.
  • "We understand the intricacies of CRM implementation in the MedTech industry and have crafted this accelerator to not only address those challenges but to provide a clear path forward.

Vision Sensing Acquisition Corp. Announces Definitive Agreement and Plan of Merger with Mediforum Co., Ltd

Retrieved on: 
화요일, 1월 16, 2024
Pub, State, Research, VSAC, CIPN, Biotechnology, Stroke, Mergers and acquisitions, Quality of life, PD, Alzheimer's disease, Acquisition, Safety, Drug development, Neuropathic pain, Peripheral neuropathy, DPN, Pharmaceutical industry

Subject to the terms and conditions set forth in the Merger Agreement, upon the closing of the transactions, the combined company will be listed on NASDAQ under a new ticker symbol.

Key Points: 
  • Subject to the terms and conditions set forth in the Merger Agreement, upon the closing of the transactions, the combined company will be listed on NASDAQ under a new ticker symbol.
  • Mediforum, a leading biotechnology firm in Korea, stands as a global pioneer in biotechnology, dedicated to advancing biomedical sciences through innovative and ethical practices.
  • With a diverse portfolio ranging from anti-dementia medications to health functional foods, Mediforum is at the forefront of biomedical innovation.
  • Both the surviving corporations of Initial Merger and SPAC Merger will be direct wholly owned subsidiaries of PubCo.

Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Retrieved on: 
수요일, 12월 13, 2023
Research, Neurology, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Medicine, Safety, Pain, Aes, Vertex, Pain management, Patient, TID, Week, Diabetic neuropathy, Medical Affairs Bureau, Autonomic, VRTX, DPN, Șaeș, Neuropathic pain, Vertex Pharmaceuticals, Pharmaceutical industry, Birth control

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).
  • The study also included an active reference arm of pregabalin to support the evaluation of the VX-548 treatment effect.
  • VX-548 was generally well tolerated at all doses tested in the study.
  • Most adverse events (AEs) were mild to moderate and there were no serious adverse events (SAEs) related to VX-548.

BREAKTHROUGH IN DIGITAL HEALTH: WITHINGS HEALTH SOLUTIONS LAUNCHES BODY PRO 2, REVOLUTIONIZING THE DETECTION OF EARLY DIABETES COMPLICATIONS WITH THE NEXT-GEN CELLULAR SCALE

Retrieved on: 
화요일, 11월 14, 2023
Motivation, ESC, Research, Activator (genetics), Diabetic foot, Risk, Body, Patient, Weather, Nature, Withings, Ulcer, Type 2 diabetes, Electrochemical skin conductance, Forecasting, Body composition, DPN, LCD, Biomarker, Diabetes, Pharmaceutical industry, Mobile phone, Medical device

BOSTON, Nov. 14, 2023 /PRNewswire/ -- Today, on World Diabetes Day, Withings Health Solutions provides a leap forward for the digital health industry with the launch of Body Pro 2, a revolutionary device redefining the nature and use of cellular-connected smart scales. Body Pro 2 is the result of years of research and development, consultation with hundreds of digital health partners and clinicians, and embodies Withings' vision that digital health needs to be a better experience for all stakeholders. It combines habit-forming user features with a pioneering modular approach to manage chronic conditions within one versatile device. Its core capabilities allow care teams to capture advanced health metrics such as weight and body composition while additional and optional health modules unlock the ability to track advanced and clinically validated biomarkers typically only available in a professional setting.  

Key Points: 
  • Prevention of type 2 diabetes and diabetes-related complications is the focus of the final year of the World Diabetes Day 2021-23 theme, Access to Diabetes Care.
  • Body Pro 2's first module is prescription-only (Rx) and aims to improve the way patients with diabetes are taken care of.
  • With this module care teams can monitor one of the biggest challenges in diabetes, diabetic foot health, which is often overlooked.
  • 1
    With Body Pro 2, Withings Health Solutions reinforces its value proposition to the digital health industry.

'Listen to your patients for early identification of Peripheral Neuropathy' say leading Health Experts at P&G's #KNOWTHESIGNS Scientific Forum

Retrieved on: 
월요일, 11월 6, 2023
Global Medical Device Nomenclature, Patient, Ulcer, Education, PN, Prickle (protein), Neuropathic pain, Neurology, Assistant, Facial muscles, Physician, Prevalence, IDF, Burning Sensations, Health, International Diabetes Federation, DPN, Type 2 diabetes, WDD, Finger, Foot, Hypoesthesia, Senior, AMA, Prediabetes, Paresthesia, Quality of life, Bethesda Hospital, The, Extremities, Risk, P&G, Peripheral neuropathy, Lyceum, Trial of the century, B, Pharmacist, Ankle, Amputation, Diagnosis, Consultant, Infection, Dietary supplement, Pharmaceutical industry, Diabetes

The signature event saw deliberations on the latest clinical guidance on diagnoses and treatment of Peripheral Neuropathy (PN) in Diabetes and Pre-Diabetes.

Key Points: 
  • The signature event saw deliberations on the latest clinical guidance on diagnoses and treatment of Peripheral Neuropathy (PN) in Diabetes and Pre-Diabetes.
  • With Diabetes Mellitus Type 2 being the leading cause of PN, its increasing prevalence is closely linked to the rise in the number of diabetics.
  • B vitamin deficiency and polymedication are other high-risk factors along with diabetes, leading to peripheral nerve damage.
  • Patients should be educated about the importance of regular foot and DPN examinations, glycemic control, and adherence to prescribed medications.

P&G Health commemorates World Diabetes Day 2023 with innovative AI-based Experiential Campaign #KnowtheSigns

Retrieved on: 
수요일, 11월 1, 2023
Digital, Ageing, PN, Prickle (protein), Life, Prevalence, Burning Sensations, Diabetes, DPN, Artificial intelligence, Hypoesthesia, Senior, Quality of life, Somatosensory system, Paresthesia, B, Patient, Diagnosis, Nerve, Dietary supplement, B vitamins, Health, Peripheral neuropathy

SINGAPORE, Nov. 1, 2023 /PRNewswire/ -- Ahead of World Diabetes Day 2023, P&G Health, makers of Neurobion, continued awareness efforts with an innovative #KnowtheSigns campaign to help consumers and healthcare professionals understand the connection between Diabetes and Pre-Diabetes with Peripheral Neuropathy (PN) and Vitamin B Deficiency for timely detection, treatment, and improved quality of life.

Key Points: 
  • SINGAPORE, Nov. 1, 2023 /PRNewswire/ -- Ahead of World Diabetes Day 2023, P&G Health, makers of Neurobion, continued awareness efforts with an innovative #KnowtheSigns campaign to help consumers and healthcare professionals understand the connection between Diabetes and Pre-Diabetes with Peripheral Neuropathy (PN) and Vitamin B Deficiency for timely detection, treatment, and improved quality of life.
  • With Diabetes Mellitus being the leading cause1 of PN, the increasing prevalence of PN is closely linked to the rise in the number of diabetic patients.
  • Symptoms of PN include numbness, tingling, prickling, and burning sensations in the hands and feet.
  • B vitamin deficiency and aging are other high-risk factors along with diabetes, leading to peripheral nerve damage.

DermBiont Announces First Close of $35.2 Million in a Series B Financing to Advance First-in-Class Targeted Topical Dermatological Therapeutics

Retrieved on: 
화요일, 10월 24, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Olive, FDA, Viking Global Investors, Food, Hyperpigmentation, Therapy, PKC, Skin, DPN, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Laser, Melasma, Physician, Recurrence, Venture round, Civilization, Dermatology, Safety, SKS, SK, Series, Patient, AKT, Dermatosis papulosa nigra, Pharmaceutical industry, Dietary supplement

DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes.

Key Points: 
  • DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes.
  • The Series B was led by new institutional investor, Double Point Ventures, and includes continued support from Viking Global Investors, Civilization Ventures, Olive Tree Capital, and others.
  • These products prioritize the patient experience by addressing the root cause of both diseases with excellent efficacy, safety, and tolerability.
  • Phase 2b open label clinical trial in 10 subjects with DPN (Dermatosis Papulosa Nigra) treated with SM-020 gel 1% twice daily for 28 days.